Results from VERITAC-2, an open-label randomized phase III study conducted on "ER-positive HER2- negative advanced breast cancer patients...receiving endocrine therapy plus a CDK4/6 inhibitor" to measure progression-free survival, was reported at the 2025 ASCO Annual Meeting. Based on findings from VERITAC-2, "vepdegestrant monotherapy showed encouraging clinical activity in patients who had received multiple previous lines of treatment for ER-positive, HER-2 negative ABC."
To read more about VERITAC-2, click here.
Sources mentioned:
- Campone M, De Laurentiis M, Jhaveri K, et al. for the VERITAC-2 Study Group. Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer . NEJM; Published online 31 May 2025. DOI: 10.1056/NEJMoa2505725
- Hamilton EP, De Laurentiis M, Jhaveri K, et al. Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study . J Clin Oncol 2025;43(suppl 17):abstr LBA1000. DOI: 10.1200/JCO.2025.43.17_suppl.LBA1000
Longer progression-free survival with vepdegestrant over fulvestrant in ESR1-mutated disease addresses a very specific and common resistance problem after endocrine therapy. An oral degrader that works where fulvestrant stops working gives patients a meaningful next option without chemotherapy. This is the kind of evidence the oncology brothers discussions keep returning to — a biomarker-defined subgroup actually getting a better drug, not just a new one.
ReplyDelete